T6654
Ticlopidine hydrochloride
analytical standard, for drug analysis
동의어(들):
5-(o-Chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine
조직 및 계약 가격을 보려면 로그인를 클릭합니다.
크기 선택
보기 변경
제품정보 (DICE 배송 시 비용 별도)
실험식(Hill 표기법):
C14H14ClNS · HCl
CAS 번호:
Molecular Weight:
300.25
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
EC Number:
258-837-4
MDL number:
Quality Segment
assay
≥99%
technique(s)
HPLC: suitable, gas chromatography (GC): suitable
application(s)
forensics and toxicology
pharmaceutical (small molecule)
veterinary
format
neat
SMILES string
Cl.Clc1ccccc1CN2CCc3sccc3C2
InChI
1S/C14H14ClNS.ClH/c15-13-4-2-1-3-11(13)9-16-7-5-14-12(10-16)6-8-17-14;/h1-4,6,8H,5,7,9-10H2;1H
InChI key
MTKNGOHFNXIVOS-UHFFFAOYSA-N
Gene Information
human ... P2RY12(64805)
Application
Ticlopidine hydrochloride has been used as an analytical standard to investigate the developmental toxicity and teratogenic potential of ticlopidine in Xenopus laevis embryos and human endothelial cells using a frog embryo teratogenesis assay-Xenopus (FETAX) and blood and lymph vessel formation assay.
Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.
Still not finding the right product?
Explore all of our products under Ticlopidine hydrochloride
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
저장 등급
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
Characterization of ticlopidine-induced developmental and teratogenic defects in Xenopus embryos and human endothelial cells.
Park SM, et al.
Chemico-Biological Interactions, 240, 172-178 (2015)
Morten Lamberts et al.
Circulation, 129(15), 1577-1585 (2014-01-29)
The optimal long-term antithrombotic treatment of patients with coexisting atrial fibrillation and stable coronary artery disease is unresolved, and commonly, a single antiplatelet agent is added to oral anticoagulation. We investigated the effectiveness and safety of adding antiplatelet therapy to
Stephen D Wiviott et al.
Lancet (London, England), 382(9892), 605-613 (2013-08-21)
Treatment with prasugrel and aspirin improves outcomes compared with clopidogrel and aspirin for patients with acute coronary syndrome who have had angiography and percutaneous coronary intervention; however, no clear benefit has been shown for patients managed first with drugs only.